Ethiopia

**Population 2017**

<table>
<thead>
<tr>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality (excludes HIV+TB)</strong></td>
<td>25 (16–37)</td>
</tr>
<tr>
<td><strong>Mortality (HIV+TB only)</strong></td>
<td>3.6 (2.5–5)</td>
</tr>
<tr>
<td><strong>Incidence (includes HIV+TB)</strong></td>
<td>172 (121–232)</td>
</tr>
<tr>
<td><strong>Incidence (HIV+TB only)</strong></td>
<td>12 (8.6–17)</td>
</tr>
<tr>
<td><strong>Incidence (MDR/RR-TB)</strong></td>
<td>5.5 (2.9–8.8)</td>
</tr>
</tbody>
</table>

**Estimates of TB burden**, 2017

<table>
<thead>
<tr>
<th>Mortality (excludes HIV+TB)</th>
<th>25 (16–37)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>3.6 (2.5–5)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>172 (121–232)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>12 (8.6–17)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)</td>
<td>5.5 (2.9–8.8)</td>
</tr>
</tbody>
</table>

**TB case notifications, 2017**

<table>
<thead>
<tr>
<th>Total notified</th>
<th>117 705</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse</td>
<td>116 725</td>
</tr>
</tbody>
</table>

- **% tested with rapid diagnostics at time of diagnosis**
  - % with known HIV status
  - % pulmonary
  - % bacteriologically confirmed among pulmonary

**Universal health coverage and social protection**

- **TB treatment coverage (notified/estimated incidence), 2017**
  - % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status
  - % pulmonary
  - % bacteriologically confirmed among pulmonary

**Drug-resistant TB care, 2017**

- **Estimated MDR/RR-TB cases among notified pulmonary TB cases**
  - 2.7% (1.6–4.1) |
  - 14% (6.7–25) |
- % notified tested for rifampicin resistance
  - 38 501 |
- MDR/RR-TB cases tested for resistance to second-line drugs
  - 205 |
- Laboratory-confirmed cases
  - MDR/RR-TB: 680, XDR-TB: 4 |
- Patients started on treatment
  - MDR/RR-TB: 680, XDR-TB: 4 |

**Treatment success rate and cohort size**

- % notified tested for rifampicin resistance
  - 38 501 |
- MDR/RR-TB cases tested for resistance to second-line drugs
  - 205 |
- Laboratory-confirmed cases
  - MDR/RR-TB: 680, XDR-TB: 4 |
- Patients started on treatment
  - MDR/RR-TB: 680, XDR-TB: 4 |

**TB preventive treatment, 2017**

- % of HIV-positive people (newly enrolled in care) on preventive treatment
  - 45% |
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment
  - 11% (9.9–12) |

**TB financing, 2018**

- National TB budget (US$ millions)
  - 93 |
- Funding source: 11% domestic, 33% international, 56% unfunded |

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed